Ron Cooper Talks PFIC and A4250

Sdílet
Vložit
  • čas přidán 5. 07. 2024
  • Ron Cooper, CEO of Albireo Pharmaceuticals, talks the inception of the company, their lead compound A4250 (which is in clinical development for the treatment of progressive familial intrahepatic cholestasis (PFIC)), and why treating children with rare liver diseases is so important.
  • Věda a technologie

Komentáře •